Millar Robert P, Newton Claire L
Medical Research Council (MRC) Human Reproductive Sciences Unit, The Queen's Medical Research Institute, Edinburgh, Scotland, United Kingdom.
Mol Endocrinol. 2010 Jan;24(1):261-74. doi: 10.1210/me.2009-0473. Epub 2009 Dec 17.
I (R.P.M.) presented "The Year In G Protein-Coupled Receptor Research" at ENDO 2009. I first described the diversity of ligands and the five families into which the approximately 800 G protein-coupled receptors (GPCRs) are grouped, their basic structural architectures, their preeminent role in signaling, and the enormous scope for developing drugs targeted at GPCRs. I then spoke about some of the exciting breakthroughs in solving the atomic level structures of the active state of rhodopsin, beta(2)-adrenergic, beta(1)-adrenergic, and A(2A)-adenosine receptors. I also described studies on the structural changes accompanying the activation of the rhodopsin family of GPCRs. From these recent technical advances, we can anticipate that many more GPCR structures will emerge, which will afford us greater insight into their common and unique structural features and, particularly, the mechanisms underlying their activation. These insights will guide us in our understanding of how GPCRs operate, both in the normal and pathological situation. Although these crystal structures are highly informative, it is important to recognize that they represent static frozen conformations of a single GPCR state. New biophysical techniques are therefore being utilized to facilitate the dynamic monitoring of GPCR structural changes in relation to ligand activation. Solving of the crystal structures of GPCRs has also presented the real possibility of using the information of the ligand-binding pocket to allow in silico screening for novel small-molecule ligands. I then reviewed the concept of ligand-induced selective signaling of GPCRs, which is opening up new insights into more selective drug development. The assembly of GPCRs as homo- and heterooligomers and their phosphorylation and association with a vast array of trafficking and signal-modulating proteins are emerging as major mechanisms underlying the functioning of GPCRs. Differential expression and recruitment of these proteins provide a mechanism for subtle physiological regulation of cellular activity. Finally, I mentioned some of the GPCRs that have lately come to the fore as novel regulators in endocrinology. These included fatty acid-specific GPCRs expressed in pancreatic beta-cells and novel neuroendocrine GPCRs regulating reproduction.
我(R.P.M.)在2009年内分泌学会年会上发表了“G蛋白偶联受体研究年度回顾”的演讲。我首先描述了配体的多样性以及大约800种G蛋白偶联受体(GPCR)所属的五个家族,它们的基本结构架构,它们在信号传导中的卓越作用,以及开发针对GPCR的药物的广阔前景。然后我谈到了在视紫红质、β₂ -肾上腺素能、β₁ -肾上腺素能和A₂A -腺苷受体活性状态的原子水平结构解析方面取得的一些令人兴奋的突破。我还描述了关于GPCR视紫红质家族激活时伴随的结构变化的研究。从这些最新的技术进展来看,我们可以预期会出现更多的GPCR结构,这将使我们更深入地了解它们的共同和独特结构特征,特别是它们激活的潜在机制。这些见解将指导我们理解GPCR在正常和病理情况下的运作方式。尽管这些晶体结构提供了丰富的信息,但重要的是要认识到它们代表的是单个GPCR状态的静态冻结构象。因此,正在利用新的生物物理技术来促进对GPCR与配体激活相关的结构变化进行动态监测。GPCR晶体结构的解析也带来了利用配体结合口袋信息进行计算机辅助筛选新型小分子配体的实际可能性。然后我回顾了GPCR配体诱导的选择性信号传导的概念,这为更具选择性的药物开发开辟了新的思路。GPCR作为同型和异型寡聚体的组装以及它们的磷酸化以及与大量运输和信号调节蛋白的结合正在成为GPCR功能的主要机制。这些蛋白的差异表达和募集为细胞活动的精细生理调节提供了一种机制。最后,我提到了一些最近在内分泌学中作为新型调节剂崭露头角的GPCR。这些包括在胰腺β细胞中表达的脂肪酸特异性GPCR和调节生殖的新型神经内分泌GPCR。